Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors. In clinical trials, ATR inhibitors have demonstrated efficacy as a treatment for various types of cancer,… Read More
New research has provided insight into the biological mechanisms that may contribute to poor outcomes in some cases of neuroblastoma. A high-risk form of the disease that is difficult to treat is often associated with mutations in the ATRX gene, which controls the expression of multiple sections… Read More
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has dosed the first patient in the randomised Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye. Roginolisib is an orally dosed small molecule allosteric modulator of PI3Kδ. Read More
Reportedly for the first time, researchers from the University of Bath have identified promising drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it. Transcription factors are proteins that act as ‘master switches’ of gene activity and play a key role in cancer… Read More
Scientists have demonstrated that glioblastoma (GBM) tumour stem cells became less able to proliferate and invade tissues when the production of the prion protein was blocked, highlighting a potential new therapeutic target. GBM, which accounts for nearly half (49%) of all brain tumours, has an extremely low… Read More
Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies. The trial included patients with acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute… Read More
Dr Jason Williams, Founder and Director of Interventional Oncology and Immunotherapy at The Williams Cancer Institute, discusses leveraging immunotherapy and cryoablation for a new era in cancer treatment. The paradigm of cancer treatment is shifting. For decades, chemotherapy and radiation have been the pillars of oncology, but their limitations are becoming… Read More
Researchers have combined immunotherapy and chemotherapy to offer new hope for patients with thymic carcinoma, a rare and aggressive cancer. Thymic carcinoma is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy. Now, researchers… Read More
Vivace Therapeutics has announced the closing of $35 million Series D financing to support the company’s small molecule cancer therapeutics targeting the Hippo pathway. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support… Read More
Bantam Pharmaceutical, a company targeting selective modulation of mitochondrial dynamics in cancer, is proceeding with a Phase I clinical trial evaluating BTM-3566 in relapsed/refractory (R/R) mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical… Read More
Cathie Miller, PhD, Senior Director of Product Marketing at BioIVT, discusses biospecimens and analytical techniques supporting the rapid evolution of ADCs in oncology. Antibody-drug conjugates (ADCs) are making significant strides forward as targeted cancer therapies. By coupling the specificity of antibodies with the potency of cytotoxic drugs, ADCs aim to… Read More
A team of international researchers have secured £1.5 ($1.9) million funding from Cancer Research UK (CRUK) to study the genetic secrets of childhood cancer neuroblastoma. The project will be led by scientists at the University of Sheffield, alongside colleagues from The Institute of Cancer Research (ICR), Kings… Read More
Scientists have developed a tool which helps them better understand cancer’s survival tactics and could eventually lead to new treatments for dozens of cancers. ‘Synthetic lethality’, the tactic of blocking pathways that cancer cells rely on, has so far mainly been successful in patients with BRCA-mutated breast,… Read More
Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round. Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. The newly formed company, with headquarters in Seattle and Singapore, intends to use the proceeds… Read More
DDW’s Diana Spencer speaks to Dan Tovar, Senior Director, Head of Cell Therapy ACE Midsize Markets, Medical Affairs at Kite Pharma, about the current landscape for cell therapies and what can be done to improve patient access. DS: Kite has pioneered cell therapy, with Yescarta (axicabtagene ciloleucel) as one of… Read More
An experimental cancer treatment developed by researchers at the Melanoma Institute Australia paves the way for a clinical trial to be conducted by researchers at the Brain Cancer Centre in Melbourne. It is the first documented use of neoadjuvant triple immunotherapy in glioblastoma, involving a combination of… Read More
